The Novemanalyst and investor event will feature presentations from key opinion leaders, Christie M. Placebo-adjusted mean percent reductions were 70.5% for patients receiving 10 mg every 12 weeks, 97.4% for patients receiving 75 mg every 12 weeks, 101.1% for patients receiving 225 mg every 12 weeks and 100.5% for patients receiving 225 mg every 24 weeks. At week 36, Lp(a) increased by a mean of 3.6% in the placebo arm, whereas there were substantial reductions of Lp(a) levels in all olpasiran arms. 6 Late-Breaking Science Session and simultaneously published in the New England Journal of Medicine. These data were presented during the Nov. ARO-ANG3 has been well tolerated with treatment emergent adverse events reported to date consistent with those expected in this patient population and with associated underlying comorbidities.Īmgen also presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of TRiM-enabled investigational olpasiran in adults with elevated lipoprotein(a) levels (greater than 150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 was also associated with relative reduction in liver fat fraction at week 24, with no adverse events related to liver function test changes reported to date. In the ARCHES-2 study in subjects with mixed dyslipidemia who had baseline median TGs of 226 mg/dL, treatment with ARO-ANG3 at doses of 50 mg, 100 mg, or 200 mg resulted in substantial reductions of ANGPT元 up to 71% at week 8, TGs up to 59% at week 16, and LDL-C up to 32% at week 16. ARO-APOC3 has been well tolerated with treatment emergent adverse events reported to date that reflect the underlying comorbidities and conditions of the population under study. In the SHASTA-2 study in subjects with severe hypertriglyceridemia who had baseline triglycerides (TGs) of greater than 500 mg/dL, treatment with ARO-APOC3 at doses of 10 mg, 25 mg, and 50 mg all durably decreased APOC3 up to 87%, TGs up to 86%, non-HDL-C up to 45%, and increased HDL-C up to 99% through the week 16 timepoint. Our confidence in the potential of these investigational medicines continues to grow as we approach the start of multiple potentially pivotal Phase 3 studies with the goal to get these important medicines to the patients that need them.” “ARO-APOC3, ARO-ANG3, and olpasiran were all highly active at silencing their respective gene targets, which resulted in encouraging changes in multiple relevant lipid and lipoprotein levels.

The totality of these data demonstrates the significant progress achieved in RNAi drug development and they specifically suggest a potential future treatment paradigm where RNAi may be prominently leveraged in preventive cardiology,” said Javier San Martin, M.D, Arrowhead’s chief medical officer. “Our team and our partners at Amgen collectively showed promising new clinical data across three late-breaking AHA 2022 presentations on investigational candidates, ARO-APOC3, ARO-ANG3, and olpasiran, which were all developed utilizing Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) technology. The company will also host a virtual analyst and investor event on November 9, 2022, at 10:00 am ET to discuss these data and Arrowhead’s plans for future clinical development of ARO-APOC3 and ARO-ANG3. (NASDAQ: ARWR) today announced the presentation of new clinical data on its pipeline of investigational RNAi-based cardiometabolic medicines, ARO-APOC3, ARO-ANG3, and olpasiran, which is being developed by Amgen, in three late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022, being held in Chicago. Company will host a virtual analyst and investor event on November 9, 2022 Olpasiran reduced lipoprotein(a) levels by more than 95% in patients with established ASCVD

ARO-ANG3 decreased triglycerides by 59%, LDL-C by 32%, and was associated with a relative reduction in liver fat fraction in patients with mixed dyslipidemia

ARO-APOC3 decreased triglycerides by 86%, and non-HDL-C by 45% while increasing HDL-C by 99% in patients with severe hypertriglyceridemia

Yahoo finance arwr conversations